Severe epidermal necrolysis after bortezomib treatment for multiple myeloma

Acta Haematologica

Volumn 118, Issue 2, 2007, Pages 65-67

  Fang, Baijun ^a   Song, Yongping ^a   Ma, Jie ^b   Zhao, Robert C ^b  

^a HENAN UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; M PROTEIN; THALIDOMIDE;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG RESPONSE; EPIDERMOLYSIS; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PURPURIC RASH; SKIN MANIFESTATION; SKIN TOXICITY; VASCULITIS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; EPIDERMAL NECROLYSIS, TOXIC; FATAL OUTCOME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; VASCULITIS, HYPERSENSITIVITY;

EID: 34548697755     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102604     Document Type: Article

References (16)

1. Pour L, Hajek R, Zdenek A, Krejci M, Krivanova A, Vorlicek J: Skin lesions induced by bortezomib. Haematologica 2005;90:44.
2. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
3. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
4. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-1520.
5. Trent J, Halem M, French LE, Kerdel F: Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg 2006;25:91-93.
6. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK: High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005;321-326.
7. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam el-A, Nazeha el-B: Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004;43:847-851.
8. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H: A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61.
9. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
10. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC, SUMMIT/CREST Investigators: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-934.
11. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
12. San-Miguel JF, Richardson P, Sonneveld P: Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 2005;106:366.
13. Rosinol L, Montoto S, Cibeira MT, Blade J: Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 2005;165:464-465.
14. Cibeira MT, Mercadal S, Arenillas L, Muntanola A, Salamero O, Blade J: Bortezomib-induced rhabdomyolysis in multiple myeloma. Acta Haematologica 2006;116:203-206.
15. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, Ozawa K, Oshimi K: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492-3494.
16. Wolkenstein P, Roujeau JC, Revuz J: Drug-induced toxic epidermal necrolysis. Clin Dermatol 1998;16:399-409.